KLRS.US Kalaris Therapeutics, Inc.

Healthcare Biotechnology USA Stocks
1.57 USD
Close of Nov 15, 2026
1.55 11.88
Market cap
USD 37.5M
P/E
-
P/B
0.79x
ROE
-93.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is KLRS.US undervalued?

Graham number

The Graham number of Kalaris Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kalaris Therapeutics, Inc. fundamental analysis

No fundamental analysis for Kalaris Therapeutics, Inc. yet.

Kalaris Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly know…

Full company profile